key: cord-0847280-k5wqrf1c
authors: Min, Long; Sun, Qiu
title: Antibodies and Vaccines Target RBD of SARS-CoV-2
date: 2021-04-22
journal: Front Mol Biosci
DOI: 10.3389/fmolb.2021.671633
sha: ff80ed22e674b02446c96a86f7c26c72a0f366ba
doc_id: 847280
cord_uid: k5wqrf1c

The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vital to find effective and safe neutralizing antibodies and vaccines for COVID-19. The critical neutralizing domain (CND) that is contained in the receptor-binding domain (RBD) of the spike protein (S protein) could lead to a highly potent neutralizing antibody response as well as the cross-protection of other strains of SARS. By using RBD as an antigen, many neutralizing antibodies are isolated that are essential to the therapeutics of COVID-19. Furthermore, a subunit vaccine, which is based on the RBD, is expected to be safer than others, thus the RBD in the S protein is a more important target for vaccine development. In this review, we focus on neutralizing antibodies that are targeting RBD as well as the vaccine based on RBD under current development.

Until now, three coronaviruses, Middle-East respiratory syndrome coronavirus (MERS-CoV),severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-CoV-2, have crossed over the barrier and lead to terrible pneumonia in human (Stadler et al., 2003; Mackay and Arden, 2015; Chen B. et al., 2020) . SARS-CoV-2 has given rise to a global pandemic because it has more possibility of human-to-human infection than SARS-CoV and MERS-CoV, which results in high numbers of infections and deaths all over the world. Due to the high infection rate, it is an emergency to develop novel vaccines and drugs.

Severe acute respiratory syndrome coronavirus-2 is closely related to bat coronavirus, which generally encodes four structure proteins, namely, spike (S), membrane (M), nucleocapsid (N), and envelope (E) (Figure 1 ) (Mittal et al., 2020; Wang M.Y. et al., 2020) . The entry of the coronavirus into the cell relies on the viral spike protein (S protein) binding to a host cell receptor and human angiotensin-converting enzyme 2 (ACE2), which is primed through the serine protease TMPRSS2. TMPRSS2 entails S protein cleavage at the S1/S2 site with an N-terminal domain (S NTD ) and the receptor-binding domain (RBD, S RBD ) binding to ACE2. The interaction between RBD and ACE2 leads to the conformational change of the C-terminal subunit (S2), which entails the fusion of virus with the cellular membranes (Hoffmann et al., 2020; Walls et al., 2020; Wang M.Y. et al., 2020) .

Researchers have put plenty of effort to develop more effective and safer vaccines and drugs against coronavirus disease 2019 (COVID-19), for instance, virus-like particle vaccines, nucleic acid vaccines, subunit and adenovirus-based vector vaccines, neutralizing antibodies, and inactive and live-attenuated vaccines . The traditional neutralization mechanism is to block the receptor-binding site located between the RBD and ACE2. The high similarity of amino acids in RBD between the two viruses can enhance the ability of neutralizing antibodies. Recently, numerous neutralizing antibodies have been found to target the RBDs of MERS-CoV or SARS-CoV (Du et al., 2009 (Du et al., , 2017 Chen W.H. et al., 2020) . Therefore, searching for neutralizing antibodies that target the RBD of SARS-CoV-2 is essential in the design of the SARS-CoV-2 vaccine.

In this review, we have discussed the recent development of RBD-targeting vaccines and neutralizing antibodies, which have a strong ability to inhibit viral entry through disrupting the binding between RBD to the receptor ACE2, which could provide a wider perspective to the design of useful therapeutic approaches against COVID-19.

The similar sequence of RBD between SARS-CoV and SARS-CoV-2 is close to 73.5% , and they share the same receptor ACE2, so it is possible that SARS-CoV RBDtargeting antibodies can exhibit cross-reactivity against SARS-CoV-2. A few antibodies which target SARS-CoV have displayed neutralizing capabilities to SARS-CoV-2 (Table 1) (Ho, 2020) .

One of the antibodies called nanobody is a novel and unique class of antigen-binding fragments (Fab) with superior characteristics, such as small size, robust antigen-binding affinity, high stability, access to more epitopes, and low production expense, which make it a suitable antibody for the treatment (Jovcevska and Muyldermans, 2020; Koenig et al., 2021) . Identifying from a llama that is immunized with COVID-19 spike and MERS-CoV S protein, the nanobody VHH-72, a SARS-CoV RBD-directed single-domain antibody (sdAb), disrupts the interaction between RBD and ACE2 and cross-neutralizes against SARS-CoV-2. Owing to its rapid dissociation, the binding affinity of VHH-72 to SARS-CoV-2 is weaker than that of VHH-72 to SARS-CoV. To overcome this disadvantage, a bivalent SARS VHH-72 (VHH-72-Fc) has been developed, and it exhibits the neutralizing activity with an IC 50 value of ∼0.2 µg/mL in a SARS-CoV-2 pseudovirus neutralization assay . One antibody named S309 targets a conserved glycan-containing epitope within the S protein on the front end of the RBD in the open and close S state and exhibits cross-reactivity toward SARS-CoV and SARS-CoV-2 (Pinto et al., 2020) . In addition, nonmonoclonal antibodies (NMAbs) identified through a memory B-cell repertoire from a patient with SARS can cross-neutralize against SARS-CoV-2. Up to now, eight antibodies have been identified to target the RBD of SARS-CoV-2. The median inhibitory concentration (IC 50 s) of the RBD-directed nAbs varies from 0.05 to 1.4 mg/mL, among which ADI-55689 interacts with the fringe place of the ACE2-binding region, which is close to the conservative center domain of the RBD, while ADI-56046 binds to some extent approximately in foreign lands on the flexible tip of the RBD that exhibits neutralizing activity and competes with hACE2 (Wec et al., 2020) . 47D11, from immunized transgenic H2L2 mice that are sequentially done with the purified S protein, binds to the conserved region of RBD distant from the spikereceptor interactive binding sites and inhibits the binding of ACE2 and S protein (Jahanshahlu and Rezaei, 2020) . Moreover, a few SARS-CoV RBD-based mouse monoclonal antibodies (mAbs), such as 7B11 and 18F3, have shown cross-reactivity against SARS-CoV-2. 7B11 can prevent SARS-CoV or SARS-CoV-2 from binding to ACE2, but 18F3 cannot, which indicates that their epitopes of the receptor-binding site on RBD are different (Tai et al., 2020) .

Through phage display technology, a potent humanized NMAb H014 is screened out to target the RBD of SARS-CoV and exhibits cross-neutralizing activity against SARS-CoV-2. Moreover, IgG and Fab fragments of H014 could target the RBD of both SARS-CoV and SARS-CoV-2 to generate neutralization at subnanomolar concentrations with IC 50 values of 1 and 3 nM against SARS-CoV and SARS-CoV-2 pseudovirus infection, respectively, and with IC 50 value of 38 nM against authentic SARS-CoV-2 virus (Lv Z. et al., 2020) .

CR3022 identified from a SARS survivor exhibits a lower affinity to SARS-CoV-2 than SARS-CoV. The epitope of CR3022 is exposed only when at least two out of the three S B domains of a spike-glycoprotein trimer are in the open conformation Yuan et al., 2020) . Recently, Huo et al. found that CR3022 destroys the perfusion spike trimer with T 1/2 at room temperature in the absence of ACE2, which is unlike the traditional mechanism of neutralizing coronaviruses by blocking receptor interaction. Furthermore, this leads to a slightly higher neutralization of the antibody, and the (non-inactivated) virus is cleaned off the cells within a short time. In addition, unlike antibodies that compete with ACE2, the ACE2-RBD-binding domain does not overlap with the epitope of CR3022; therefore, it is unusually resistant to virus escape (Huo et al., 2020b) . CR3022 has a higher affinity to the SARS-CoV-2 P384A mutant and shows a similar potency of neutralizing activity against SARS-CoV. Conclusively, CR3022 could be used as a potential candidate therapeutic, alone or in combination with other antibodies for the treatment of COVID-19 (Yi et al., 2020) .

It is relatively common to find antibodies that have the crossbinding ability to both SARS-CoV-2 and SARS-CoV RBD, but cross-neutralizing responses may be rare . It is essential to design and develop potential antibodies which target SARS-CoV-2 specifically and selectively ( Table 2) . The human phage display technology is a powerful tool that has revolutionized the development of identifying and optimizing antibodies, providing breakthrough points for further applications in the invention of therapeutic mAbs in antiinfectious diseases (Alfaleh et al., 2020) .

This signal-domain antibody 3F11 completely blocks the binding of RBD to ACE2 and shows neutralizing activity FIGURE 1 | Schematic diagram of the SARS-CoV-2 coronavirus particle. Four structure proteins contain the envelope protein (E), nucleocapsid protein (N), spike protein (S), and membrane protein (M). SARS-CoV-2 virus enters the cell through the S protein on the surface of SARS-CoV-2 by means of binding with its receptor ACE2. The S protein is mainly divided into S1, which contains RBD, and S2 subunits. Created by BioRender.com. ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; RBD, receptor-binding domain. (Huo et al., 2020b) with an IC 50 value of 0.4360 µg/mL in a SARS-CoV-2 virus neutralization assay. Moreover, in a SARS-CoV-2 pseudotyped virus entry assay, when sdAbs fuses with the human lgG1 crystallizable fragment (Fc) fragment, the recombinant 3F11 neutralizes against SARS-CoV-2 with an IC 50 value of 0.0020 µg/mL (Yu et al., 2020) . BD-368-2 was isolated from 60 donors by using highthroughput single-cell RNA and VDJ sequencing of antigenenriched B cells, which neutralizes the pseudotyped SARS-CoV-2 and authentic SARS-CoV-2 with an IC 50 of 1.2 and 15 ng/mL, respectively. BD-368-2 targets the epitope which overlaps with the ACE2-RBD binding domain; therefore, BD-368-2 could be an effective NMAbs-targeting RBD .

A high-affinity mAb, IgG1 ab1, was rapidly identified from phage-displayed Fab, single-chain fragment variable region (scFV), and VH libraries. IgG1 ab1 shows neutralizing activity against authentic SARS-CoV-2 infection through preventing RBD to ACE2. The sequence of IgG1 ab1 has a relatively low number of mutations and no safety deficiencies; thus, lgG1 ab1 has become a potential therapeutic for SARS-CoV-2 infection (Li W. et al., 2020) .

CB6, which was identified through human B cells of convalescent donors, prevents the binding of RBD to its receptor ACE2 by steric hindrance and competition with interface residues. CB6 exhibits neutralizing activity against pseudovirus SARS-CoV-2 with ND 50 values of 0.036 µg/ml .

Four antibodies, B38, H4, H2, and H4, which are bound to the epitopes of RBD, are identified from the peripheral blood of COVID-19 convalescent donors. H4 suppresses SARS-CoV-2 infection with an IC 50 value of 0.896 µg/mL, while B38 has a higher potency to inhibit SARS-CoV-2 virus infection with an IC 50 value of 0.177 µg/mL. The two antibodies act on different domains, so there is no competition between B38 and H4, which enables them to be used in combination for targeting the virus to prevent immune escape in clinics (Dong et al., 2020; Jahanshahlu and Rezaei, 2020) .

P2C-1F11, P2C-1A3, and P2B-2F6 are screened from the plasma of convalescing patients. The P2B-2F6 Fab competes with BD-368-2 lgG Human Disturbs the RBD-ACE2 interaction Ab1 lgG1 lgG Human Disturbs the RBD-ACE2 interaction (Li W. et al., 2020) CB6 lgG Human Competes with ACE2 for binding to RBD B38 H4 lgG Human Competes with ACE2 for binding to RBD (Dong et al., 2020; Jahanshahlu and Rezaei, 2020) B5 lgG Human Binds to RBD but partially competes with ACE2 (Dong et al., 2020; Jahanshahlu and Rezaei, 2020) H2 lgG Human Binds to RBD but displays no competition with ACE2 (Dong et al., 2020; Jahanshahlu and Rezaei, 2020) P2C-1F11 lgG Human Disturbs the RBD-ACE2 interaction (Ju et al., 2020) P2B-2F6

P2C-1A3 rRBD-15 lgG Human Prevents the interaction of RBD-ACE2 (Ho, 2020; Yu et al., 2020) 311mAb-31B5 lgG Human Blocks the binding of RBD-ACE2 311mAb-32D4 the S protein to block the ACE2-RBD binding. P2C-1F11, P2C-1A3, and P2B-2F6 are strong inhibitors of authentic SARS-CoV-2, with IC 50 values of 0.03, 0.28, and 0.41 µg/mL, respectively (Ju et al., 2020) . rRBD-15 is identified through a synthetic human Fab antibody library and exhibits the neutralizing activity against SARS-CoV-2 pseudovirus infection with an IC 50 value of 12.2 nM (Ho, 2020; Yu et al., 2020) . 311mab-32D4 and 311mab-31B5 could prevent the binding of RBD to its receptor hACE2 with IC 50 values of 0.0450 and 0.0332 µg/mL, respectively. Moreover, 311mab-32D4 and 311mab-31B5 show the neutralizing activity against SARS-CoV-2 with IC 50 values of 0.0698 and 0.0338 µg/mL in a SARS-CoV-2 pseudotyped virus entry assay, respectively . Identified from B cells of convalescent donors by a highthroughput rapid system, CC12.1 shows neutralizing activity against SARS-CoV-2 with an IC 50 value of 0.019 µg/mL in a SARS-CoV-2 pseudotyped virus entry assay and with an IC 50 value of 0.022 µg/mL against authentic SARS-CoV-2 infection. In addition, CC6.30 and CC6.29 show neutralizing activity against SARS-CoV-2 with IC 50 values of 1 ng/mL and 2ng/mL in a SARS-CoV-2 pseudotyped virus entry assay, respectively (Rogers et al., 2020) .

Another two antibodies, COVA2-15 and COVA1-18, were obtained from B cells of convalescent donors. These antibodies have shown neutralizing activity against SARS-CoV-2 pseudovirus infection with an IC 50 value of 8 ng/mL for both and live neutralization SARS-CoV-2 infection with IC 50 values of 7 and 9 ng/mL (Brouwer et al., 2020) .

H11-H4 and H11-D4 target epitopes that are closely adjacent to and are slightly overlapping with the ACE2-binding domain to block RBD-ACE2. Furthermore, when nanobodies H11-D4 and H11-H4 are fused with lgG Fc, they also show the neutralizing activity against SARS-CoV-2. Nanobodies H11-H4 and H11-D4 bind with RBD with KD of 12 and 39 nM, respectively. Studies have shown that H11-D4 and H11-H4 have the additive neutralizing activity against SARS-CoV-2 with the CR3022 antibody because it recognizes a different binding site. Such a strategy is a good way to reduce the possibility of the virus escape by mutation (Huo et al., 2020a) .

COV2-2196 and COV2-2130, identified from the lymphocytes of convalescent donors, neutralize the SARS-CoV-2 pseudovirus infection by binding to different sites on RBD and completely prevent the interaction with hACE2. Therefore, both COV2-2196 and COV2-2130 could bind to the S protein simultaneously and exhibit a synergistic neutralizing effect on SARS-CoV-2 infection. The use of COV2-2196 and COV2-2130 alone or in combination is promising for the treatment or prevention of SARS-CoV-2 (Zost et al., 2020) .

Yu et al. identified 61 NMAbs from peripheral blood mononuclear cells (PBMCs) of five severe SARS-CoV-2 donors, among which nine NMAbs have been identified against the authentic SARS-CoV-2 infection. The most potent NMAb 2-15 could neutralize pseudotyped and authentic SARS-CoV-2 infection through competitively binding RBD with ACE2, with IC 50 of 5 and 0.7 ng/mL, respectively (Yu et al., 2020) .

A recently developed SARS-CoV-2 receptor-blocking human antibody, HA001, was found to interact with new binding sites (A475 and F486 in RBD) for neutralizing antibodies in SARS-CoV-2 but could not recognize SARS-CoV. The study indicates that there are different key epitopes between SARS-CoV and SARS-CoV-2, which provide insights to develop more specific antibody drugs and prophylactic vaccine (Yi et al., 2020) .

Using an scFv phage display library, II62, a novel scFv was identified. II62 targets a region that is adjacent and closely overlapping with the binding domain of ACE2 on the RBD. Hilal et al. found II62-scFv and its two other formats, scFv-Fc and IgG1, that target the RBD and interrupt the ACE2-RBD binding. The inhibition of RBD to its receptor ACE2 is dependent on the concentration (starting from 5 to 0.008µM). Upon tested up to 100 µg/mL against authentic SARS-CoV-2 virus, II62 does not exhibit a significant reduction in the neutralizing potential. The possible explanation is that it is only accessible in the open postfusion conformation of the S protein. S309 and S310 recognize post-fusion conformation of SARS-CoV-2 S protein, and CR3022 exhibits non-neutralizing behavior against SARS-CoV-2. Non-NAb plays an essential role in the blockage of cell surface infection in vivo without perturbing virus entry, which could be useful for improving antibody-based therapeutics and diagnostics for COVID-19 (Parray et al., 2020) .

A nanobody called n3088 was isolated from a full human sdAb library and exhibits neutralizing activity against SARS-CoV-2 by targeting a cryptic epitope located in RBD of SARS-CoV-2 (Dong et al., 2020; Wu et al., 2020) .

Upon isolating B cells specific to the SARS-CoV-2 S protein from patients infected with SARS-CoV-2 after 21 days of clinical disease onset, CV30 and CV1/CV35 exhibit neutralizing activity against SARS-CoV-2. Moreover, CV30 binds RBD in a manner that prevents the binding of ACE2 to RBD. CV1/CV35 binds to a domain distant from the RBD and has less neutralizing activity than CV30 (Seydoux et al., 2020) .

To date, over 150 SARS-CoV-2 vaccines are under development all over the world. Most recently, RBD-based SARS-CoV-2 vaccine candidates could induce a strong RBD-based neutralizing antibody response in some animals after just one dose of injection (Figure 2 ) . Herein, we summarize the development of vaccines that could induce antibodies specific to RBD (Tables 3, 4) .

Lu group developed a recombinant subunit vaccine candidate that contains the RBD of SARS-CoV-2 and the Fc fragment of human lgG, which can extend the half-life of the immunogen and enhance the responses of the long-term neutralizing antibody (Kontermann, 2011) . It is a benefit for therapeutic and economic reasons to reduce the number of usage and dosage by the extension of the half-life. Recently, many mutations in FIGURE 2 | The immune response caused through a vaccine. The mRNA of the RBD of the S protein of SARS-CoV-2 can translate on the ribosome of the host, and then the foreign protein of RBD reduces to a polypeptide to stimulate the immune system and is caught by the antigen-presenting cells (APCs) which can process the vaccine antigen and present it to the CD4 T + cells and CD8 T + cells. It acquires the ability to treat SARS-CoV-2 by activating B cells to produce antibodies and T cells to attack the infected cells. Created by BioRender.com. SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; RBD, receptor-binding domain.

Frontiers in Molecular Biosciences | www.frontiersin.org 

West China Hospital phase 2 clinical trials 0, 21 days and 0, 14, 28 days ZF2001

Anhui zhifei longcom Biologic Pharmacy Co., Ltd Phase 3 clinical trials 0, 30, and 60 days BNT162b1

BioNTech and Pfizers Phase 1/2 clinical trials 0 and 28 days (Sahin et al., 2020) ARCoV Chinese Academy of Military Medical Sciences Phase 1 clinical trials N/A SARS-CoV-2 S protein have emerged; thus, people are worried about if the current vaccines could also be helpful when those mutants exist in SARS-CoV-2. To evaluate the neutralizing activity of the RBD-Fc-based SARS-CoV-2 vaccine candidates, Liu et al. constructed eight RBD mutants of SARS-CoV-2 PSV with detectable infectivity. The results show that these natural mutations in RBD of SARS-CoV-2 PSV did not influence the neutralizing activity of the RBD-Fc-induced antisera. Moreover, the antibody induced by the RBD-Fc-specific SARS-CoV-2 vaccine could cross-neutralize the infection of a bat pseudotyped SARS-CoV WIV1 as well as the pseudotyped SARS-CoV . AdimrSC-2f (NCT04522089) is a protein subunit vaccine developed by Adimmune Corporation, which is now under phase 1 clinical trials in Taiwan (clinicaltrials.gov). AdimrSC-2f can be used to immunize an individual, with or without aluminum content as an adjuvant, to bolster an immune response that could protect them from infection with the native virus.

The recombinant vaccine (NCT04640402), developed by West China Hospital, containing residues 319-545 of the RBD of the S protein, has been ongoing in phase 2 clinical trials in China. This protein subunit vaccine is expressed in Sf9 insect cells. Individuals can be immunized and generate a specific antibody against the S-RBD protein of SARS-CoV-2, which could protect them from the infection with the native virus . ZF2001 (NCT04646590) is a recombinant protein vaccine that uses a dimeric fragment of RBD as the antigen to trigger a protective immune response. The vaccine is well tolerated and immunogenic, which is in phase 3 clinical trials in China .

A lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine, BNT162b1 (NCT04368728), encodes the trimerized RBD of the S protein of SARS-CoV-2 (Sahin et al., 2020) . The RBD antigen encoded through BNT162b1 is fused to a T4 fibrin-derived fold by trimerization to enhance its immunogenicity through a multivalent display (Tai et al., 2016) . Once vaccinated, host cells uptake the mRNA and then generate the protein which touches off the immune response against infection with SARS-CoV-2. On September 30, 2020, the BNT162b1 vaccine of BioNTech and Pfizer has entered into Phase 1/2 clinical trials, and the results show that the immunized individuals elicit a strong SARS-CoV-2-specific antibody and CD4 + and CD8 + immune responses that suggest multiple mechanisms with the potential to protect against SARS-CoV-2. However, the storage condition needs ultra-low temperature of −70 • C in a freezer, which makes it difficult to transport and store, so it is difficult to reach low-income countries due to high cost.

ARCoV, a lipid nanoparticle-encapsulated mRNA vaccine, encodes the RBD of SARS-CoV-2, which can induce strong antibodies and arouse T-cell responses against multiple epidemic SARS-CoV-2 strains in some animals. Importantly, compared with other mRNA vaccines, it could be kept at room temperature for at least 7 days. The vaccine has been tested in phase 1 clinical trials .

The two NAbs, REGN10987 and REGN10933 (NCT04519437), bind two distant regions of RBD, where the epitope of REGN10987 is on the side of the RBD, while the epitope of REGN10933 locates away from that of REGN10987, which is an advantage to avoid generating escape mutants. The variant of D614G has a pandemic in the world, but the neutralizing potency of REGN10933 and REGN10987 is not affected in the presence of this variant (Baum et al., 2020a; Yurkovetskiy et al., 2020) . The combination of antibodies has been tested in phase 3 clinical trials (Baum et al., 2020b; Hansen et al., 2020) .

VIR-7831 (GSK 4182136), which has entered phase 2/3 clinical trials, is a fully human mAb, based on the S309 which is identified from a SARS survivor, that targets the RBD of SARS-CoV-2 and is developed by Vir Biotechnology and GSK.

AZD7442 is composed of two human mAbs, COV2-2196 and COV2-2130, which are isolated from the lymphocytes of convalescent patients, that exhibit neutralizing activity against SARS-CoV-2 by disturbing the binding of ACE2-RBD. Furthermore, COV2-2196 and COV2-2130 exhibit strong neutralizing activity against some variations, such as E484K, N501Y, and D614G. AZD7442 is in phase 3 clinical trials.

LY-CoV555 is a neutralizing antibody identified from a SARS-CoV-2 survivor. LY-CoV555 has a high-affinity binding with RBD, thus exhibiting neutralizing activity against SARS-CoV-2. Recently, some studies showed that the combination of two antibodies, LY-CoV555 and LY-CoV016, have strong neutralizing activity against SARS-CoV-2 and can reduce hospitalizations and death for patients with early-stage COVID-19.

CT-P59 developed by Celltrion has entered phase 3 clinical trials. It could improve the recovery times of patients with COVID-19 and reduce progression rates of SARS-CoV-2.

SARS-CoV-2 has led to a serious ongoing global disaster and imposes a great threat to the economy and health management system all over the world. Hundred million people have been confirmed of the SARS-CoV-2 infection, and over 2 million people have died till February 2, 2021. Even though several positive efficacy results have been reported on the vaccine candidates, SARS-CoV-2 vaccines developed so far cannot meet the global demand. Vaccine candidates against SARS-CoV-2 have different compositions, from traditional wholepathogen vaccines, live-attenuated vaccines, and inactivated vaccines to various new-generation recombinant protein vaccines and vector-based vaccines. Instead of the whole virus, the new generation vaccines only contain a specific antigen or antigen from the pathogen that makes the vaccine safer than the traditional vaccines. The vaccines we discuss are mainly recombinant protein vaccines and vector-based vaccines. Because the recombinant protein vaccines use a protein fragment of RBD as the antigen, this type of vaccine has lower immunoreactivity than the whole-pathogen vaccines, but the immunogenicity of the recombinant protein vaccines is weaker than others which need multiple vaccine dosages or adjuvants, and it is easy to store and transport. The disadvantage of the recombinant subunit vaccine is that it is difficult to design a good structure of a recombinant protein and the expression system. Furthermore, this type of vaccine may need adjuvants to enhance the immunogenicity of the vaccines. As a nucleoside-modified mRNA, which is the advent of a new era in vaccinology, there are many advantages of this type of vaccine; for instance, they pose no risk of genomic integration, are easy to design, and can be manufactured rapidly. However, the mRNA vaccine need to be encapsulated; otherwise, it becomes unstable under physiological conditions, and the halflife of mRNA is short; thus, there may be many problems or side effects beyond our expectations (Koirala et al., 2020; , because the technology is too new, and there is no successful precedent, so most of the countries cannot carry out industrial production, and it may be difficult to popularize in low-income countries because of the high price. What is worse, SARS-CoV-2 is undergoing mutation, which makes it more difficult to explore vaccines. Among them, D164G is of particular note because that itself and its combination with other mutations have made the virus more infectious. Moreover, some variants, such as V483A, N234Q, Y508H, A475V, F490L, L452R, and N439tK, also have reduced sensitivity to neutralizing mAbs . Therefore, it is urgent to develop broadspectrum vaccines, neutralizing antibodies, and other therapeutic tools to fight against SARS-CoV-2.

Phage display derived monoclonal antibodies: from bench to bedside

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Overview of lethal human coronaviruses

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

A systematic review of SARS-CoV-2 vaccine candidates

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

MERS-CoV spike protein: a key target for antivirals

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Molecular mechanism of evolution and human infection with SARS-CoV-2

Perspectives on the development of neutralizing antibodies against SARS-CoV-2

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Neutralization of SARS-CoV-2 by destruction of the prefusion spike

Monoclonal antibody as a potential anti-COVID-19

The therapeutic potential of nanobodies

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Vaccines for COVID-19: the current state of play

Strategies for extended serum half-life of protein therapeutics

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody. bioRxiv

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

MERS coronavirus: diagnostics, epidemiology and transmission

COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2

Identification of an anti-SARS-CoV-2 receptor-binding domaindirected human monoclonal antibody from a naive semisynthetic library

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

SARS-beginning to understand a new virus

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

The COVID-19 vaccine race: challenges and opportunities in vaccine formulation

SARS-CoV-2: structure, biology, and structure-based therapeutics development

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies

Identification of human single-domain antibodies against SARS-CoV-2

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. medRxiv

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

A thermostable mRNA vaccine against COVID-19

Potently neutralizing and protective human antibodies against SARS-CoV-2

LM wrote the manuscript. QS revised the manuscript. Both authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2021 Min and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.